Chase Investment Counsel’s Pfizer PFE Stock Holding History

Chase Investment Counsel’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,192	Closed	-$234K	–	148
2025 Q3	$234K	Buy	+9,192	New	+$227K	0.07%	122
2025 Q1	–	Sell	-11,486	Closed	-$304K	–	142
2024 Q4	$304K	Sell	11,486 -171,298	-94%	-$4.65M	0.1%	123
2024 Q3	$5.29M	Buy	+182,784	New	+$5.33M	1.76%	22
2023 Q4	–	Sell	-34,619	Closed	-$1.15M	–	132
2023 Q3	$1.15M	Buy	34,619 +23,062	+200%	+$816K	0.57%	51
2023 Q2	$423K	Buy	11,557 +560	+5%	+$21.8K	0.21%	71
2023 Q1	$448K	Buy	10,997 +928	+9%	+$40.1K	0.25%	66
2022 Q4	$515K	Sell	10,069 -1,805	-15%	-$86.5K	0.32%	58
2022 Q3	$519K	Hold	11,874	–	–	0.33%	57
2022 Q2	$622K	Buy	11,874 +505	+4%	+$25.7K	0.34%	61
2022 Q1	$588K	Buy	11,369 +685	+6%	+$35.5K	0.26%	62
2021 Q4	$630K	Sell	10,684 -411	-4%	-$20.4K	0.25%	63
2021 Q3	$477K	Sell	11,095 -21,725	-66%	-$962K	0.21%	64
2021 Q2	$1.28M	Buy	32,820 +21,870	+200%	+$850K	0.53%	55
2021 Q1	$396K	Buy	10,950 +1,015	+10%	+$36K	0.18%	75
2020 Q4	$365K	Sell	9,935 -1,517	-13%	-$55.6K	0.16%	76
2020 Q3	$398K	Sell	11,452 -2,049	-15%	-$71.8K	0.2%	67
2020 Q2	$418K	Buy	13,501 +3,207	+31%	+$109K	0.21%	70
2020 Q1	$318K	Buy	10,294 +321	+3%	+$10.9K	0.21%	48
2019 Q4	$370K	Sell	9,973 -12	-0.1%	-$427	0.19%	86
2019 Q3	$340K	Buy	9,985 +154	+2%	+$5.6K	0.17%	83
2019 Q2	$404K	Hold	9,831	–	–	0.21%	73
2019 Q1	$396K	Buy	9,831 +1,790	+22%	+$71.7K	0.2%	73
2018 Q4	$333K	Sell	8,041 -796	-9%	-$33K	0.2%	72
2018 Q3	$369K	Buy	8,837 +1,232	+16%	+$47.4K	0.19%	68
2018 Q2	$261K	Buy	7,605 +1,212	+19%	+$41.4K	0.14%	73
2018 Q1	$215K	Sell	6,393 -1,169	-15%	-$40.2K	0.11%	79
2017 Q4	$259K	Hold	7,562	–	–	0.14%	70
2017 Q3	$256K	Hold	7,562	–	–	0.13%	72
2017 Q2	$241K	Hold	7,562	–	–	0.12%	75
2017 Q1	$245K	Buy	7,562 +832	+12%	+$26.2K	0.12%	76
2016 Q4	$207K	Sell	6,730 -3,705	-36%	-$113K	0.1%	86
2016 Q3	$335K	Hold	10,435	–	–	0.15%	92
2016 Q2	$348K	Buy	10,435 +448	+4%	+$14.3K	0.15%	80
2016 Q1	$280K	Buy	9,987 +938	+10%	+$26.8K	0.12%	88
2015 Q4	$277K	Sell	9,049 -63	-0.7%	-$1.98K	0.11%	76
2015 Q3	$271K	Buy	9,112 +590	+7%	+$18.9K	0.11%	80
2015 Q2	$271K	Hold	8,522	–	–	0.1%	85
2015 Q1	$281K	Sell	8,522 -2,002	-19%	-$63.6K	0.1%	87
2014 Q4	$311K	Hold	10,524	–	–	0.11%	84
2014 Q3	$295K	Buy	10,524 +2,002	+23%	+$56.2K	0.11%	87
2014 Q2	$239K	Hold	8,522	–	–	0.08%	95
2014 Q1	$259K	Buy	8,522 +659	+8%	+$19.6K	0.09%	90
2013 Q4	$228K	Buy	7,863 +422	+6%	+$12.3K	0.07%	103
2013 Q3	$202K	Buy	+7,441	New	+$202K	0.05%	96

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Chase Investment Counsel's PFE Position: Q4 2025 in Review

Chase Investment Counsel sold out of Pfizer (PFE) in Q4 2025, closing a stake of 9,192 shares — an estimated $234K sold.

Chase Investment Counsel first reported a position in PFE in Q3 2013 and held it in 44 quarters. The position peaked at $5.29M in Q3 2024. 2,914 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

Chase Investment Counsel reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
Chase Investment Counsel sold 9,192 Pfizer shares in Q4 2025, an estimated $234K.
Chase Investment Counsel first reported a position in Pfizer in Q3 2013 and held it in 44 quarters.
Chase Investment Counsel's Pfizer position peaked at $5.29M in Q3 2024.
2,914 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Chase Investment Counsel's 13F filing for Q4 2025, filed 5 Feb 2026.